# AMT-253 in Patients With Selected Advanced Solid Tumours

> **NCT05906862** · PHASE1 · RECRUITING · sponsor: **Multitude Therapeutics (Australia) Pty Ltd** · enrollment: 54 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** AMT-253

## Key facts

- **NCT ID:** NCT05906862
- **Lead sponsor:** Multitude Therapeutics (Australia) Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-06
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05906862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05906862, "AMT-253 in Patients With Selected Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05906862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*